Medtronic plc. Ordinary Shares (NYSE:MDT) has revealed that the InterStim system it has developed is capable of improving the quality of life for patients with overactive bladders as well as offer sustained long-term efficacy. In order to normalize the communication pathway between the brain and bladder, the system uses gentle nerve stimulation or neuromodulation. Interstim also restores the functions of the bladder by alleviating symptoms through targeting of sacral nerves.
Symptom reduction
A study conducted by InSite showed that about 82% of the patients with overactive bladders achieved therapeutic success after five years. Success in this case was defined as a 50% reduction in symptoms. In the study safety and efficiency of the system was assessed after five years in those patients who overactive bladder symptoms were bothersome and who found traditional treatments intolerable.
“This multicenter study shows that [sacral neuromodulation ] has sustained efficacy and QOL improvements and an acceptable safety profile through 5 years in OAB subjects,” read part of the study results published in Journal of Urology.
Chronic condition
With overactive bladder being a chronic condition that can have a significant impact on an individual’s quality of life by affecting intimacy, social activities and confidence, the Interstim system is a welcome innovation offering long-term relief to individuals suffering from excessive urination and urinary incontinence. For Medtronic this is a strategic move since the number of those suffering from overactive bladders and who need a solution is growing.
Growing market
In the United States, the number of individuals diagnosed with overactive bladders is estimated to be more than 37 million. This is approximately one in every six Americans. In the period between 2017 and 2021, the market for overactive bladder products is expected to grow at a compounded annual growth rate of close to 2%. This is according to an analysis report prepared by Technavio.
But like all surgical procedures, there are risks that come with the Interstim system. During implantation, unfavorable events can result such as implant site pain and undesirable stimulation change as well as ineffectiveness.
On Tuesday shares of Medtronic plc. Ordinary Shares fell by 0.24% to close the day at $85.85.